Dipartimento di Medicina interna e terapia medica

Contenuti del sito

Menu di navigazione - Torna all'inizio


Contenuto della pagina - Torna all'inizio


Paolo Gobbi

Professore Associato in quiescenza dal marzo 2018
Sede:

Unità di Medicina Interna e Gastroenterologia c/o Policlinico San Matteo - Pavia

Telefono+ 39 0382 502825
Fax+ 39 0382 502618
E-mailgobbipg@smatteo.pv.it
Orari di ricevimentoGiovedì dalle 18.00 alle 19.00
Insegnamenti

Aspetti medici attività sportiva - Scienze Motorie

CurriculumCV Gobbi
Pubblicazioni

Gobbi P.G. et al.: Prognostic validation of the International Classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance ? Clin. Cancer Res. 11, 1786 - 1790, 2005.

Baldini L., Goldaniga M., Guffanti A., Broglia C., Cortelazzo S., Rossi A., Morra E., Colombi M., Callea V., Pogliani E., Ilariucci F., Luminari S., Morel P., Merlini G., Gobbi P.G.: IgM MGUS and indolent Waldestrom macroglobulinemia recognise the same determinants of evolution into symptomatic lymphoid disorders. Proposal for a common prognostic scoring J. Clin Oncol. 20, 4662-4668, 2005.

Gobbi P.G. et al: ABVD vs. Stanford V vs. MOPPEBVCAD with optional and limited radiotherapy in advanced-stage Hodgkin’s lymphoma. Final results of a multicenter, randomized trial by the Intergruppo Italiano Linfomi. J. Clin. Oncol. (accettato, in stampa) 23, 9198-9207, 2005

Gobbi PG, et al.: MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin’s lymphoma: 10-year results, late toxicity and second tumors. Clin. Cancer Res., 12, 529-535, 2006.

Gobbi PG et al.: New insights into the role of age and carcinoembryonic antigen in the prognosis of colorectal cancer. Br. J. Cancer 98, 328-334, 2008.

Gobbi PG et al: Complete long-term response to radiotherapy of gastric early-stage marginal-zone lymphoma resistant to both anti-Helicobacter Pylori antibiotics and chemotherapy. Ann. Oncol. 20, 465-468, 2009.

Gobbi P.G: Shortened and intensified MJMA: an effective salvage therapy for relapsed and refractory lymphomas and a strong mobilizer of peripheral blood stem cells. Bone Marrow Transpl. 44, 19-25, 2009.

Morel P., Duhamel A., Gobbi P.G. et al.: International prognostic scoring system for Waldenström’s Macroglobulinemia. Blood 113, 4163-4170, 2009.

D’Arena G., Gobbi P.G., et al: Pamidronate versus observation in asymptomatic myeloma: final results with long follow-up of a randomized study. Leuk Lymphoma accepted 2010